Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/33213
Title: Influence of buprenorphine analgesia on post-operative recovery in two strains of rats.
Authors: Jablonski P.;Baxter K.;Howden B.O.
Institution: (Jablonski, Howden, Baxter) Monash University, Department of Surgery, Monash Medical Centre, 246 Clayton Road, Clayton, Vic. 3168, Australia
Issue Date: 22-Oct-2012
Copyright year: 2001
Publisher: Royal Society of Medicine Press Ltd (P.O. Box 9002, London W1A 0ZA, United Kingdom)
Place of publication: United Kingdom
Publication information: Laboratory Animals. 35 (3) (pp 213-222), 2001. Date of Publication: 2001.
Abstract: The objective of this study was to establish an effective post-operative analgesic regimen for Sprague-Dawley (SD) and Dark Agouti (DA) rats. Buprenorphine (0.01 or 0.05 mg/kg), a partial mu opioid agonist, was administered subcutaneously immediately on completion of a standardized surgical procedure, involving anaesthesia, laparotomy and visceral manipulation. Two of the four treatment groups and the saline control group received a second injection 9 h later. Behavioural observations by three independent observers provided no information in assessing pain in this model. All rats lost weight, consumed less food and water after surgery. On the first day, both SD and DA rats receiving buprenorphine lost less weight than untreated control groups. Using weight loss as an efficacy criterion, low-dose buprenorphine, given once or twice, provided effective analgesia in SD rats. A higher single dose provided no additional benefit and a second dose was detrimental, reducing body weight and food intake. In DA rats, the high dose, given twice, appeared to be more effective than the lower dose. All DA cage cohorts consumed <10% pre-operative food despite buprenorphine treatment, suggesting a higher dosage may be necessary. However, all SD and 80% DA rats who received no buprenorphine gained body weight on the second day, whereas most of the buprenorphine-treated rats continued to lose weight for another 2 days, despite increased food consumption by both strains. Buprenorphine may adversely affect intestinal function over a number of days due to its enterohepatic circulation; this effect may be more severe in DA rats. Adverse metabolic effects of buprenorphine and other opioids may preclude their use in the future if it can be shown that non-steroidal anti-inflammatory drugs (NSAIDs) provide equally effective analgesia.
DOI: http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1258/0023677011911651
PubMed URL: 11459404 [http://www.ncbi.nlm.nih.gov/pubmed/?term=11459404]
ISSN: 0023-6772
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/33213
Type: Article
Appears in Collections:Articles

Show full item record

Page view(s)

42
checked on Jan 1, 2026

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.